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Abstract In this study, we found the expression of Dachs-
hund 1 (DACH1) is downregulated while peroxiredoxin 3
(PRX3) upregulated in both lung adenocarcinoma tissues
and cells. Transfection of DACH1 can significantly downreg-
ulate PRX3 expression in targeting lung adenocarcinoma
cells. Further experimental results demonstrated the evidence
that overexpression of DACH1 resulted in significant retarda-
tion of in vitro proliferation and invasion of lung adenocarci-
noma cells. Direct upregulation of PRX3 by co-transfection of
PRX3 messenger RNA (mRNA) can prevent the above alter-
ation caused by DACH1 transfection. Besides, lower DACH1
expression significantly correlated with tumor diameter and
tumor invasion in all the 36 patients diagnosed with lung
adenocarcinoma in our hospital during the past months. In
conclusion, DACH1 can inhibit the proliferation and invasion
of lung adenocarcinoma through the downregulation of
PRX3. Decreased expression of DACH1 is involved in the
initiation and development of lung cancer, which might be
an adverse prognostic factor of lung adenocarcinoma.
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Introduction
Lung cancer is the most common cancer in men worldwide
with an age-standardized rate (ASR) of 33.8 per 100,000 and
the fourth most frequent cancer in women (13.5 per 100,000)
[1, 2]. Lung cancer is the leading cause of cancer-related mor-
tality among both men and women worldwide with approxi-
mately 160,000 deaths reported each year in the USA [3, 4].
Non-small cell lung cancer (NSCLC) constitutes approxi-
mately 80 % of all lung cancers and includes adenocarcinoma
and squamous cell carcinoma, which are histologically dis-
tinct from small cell lung cancer [5]. Although significant
advances have beenmadewith conventional therapies, includ-
ing surgery, chemotherapy, and radiotherapy, the poor prog-
nosis and low overall survival (OS) rate highlights the urgent
need for developing novel therapeutic methods [6]. Recently,
patients with activating mutations of the epidermal growth
factor receptor (EGFR) gene have shown an effective re-
sponse to small-molecule competitive inhibitors of the EGFR
tyrosine kinase such as gefitinib (Iressa, AstraZeneca) and
erlotinib (Tarceva, Roche) [7]. However, these drugs appear
to be less effective in patients without EGFR mutation [8, 9].
Besides, patients rapidly develop drug resistance, which typ-
ically occurs 8–12 months from the start of treatment [10].
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Thus, the identification of novel targets is of great importance
for curing lung cancers.
The Dachshund gene (dach) was originally cloned in
Drosophila as a dominant inhibitor of ellipse and encodes a
key component of the retinal determination gene network
(RDGN) [11]. The mammalian Dachshund 1 (DACH1) regu-
lates the expression of target genes, in part, through interacting
with DNA-binding transcription factors (c-Jun, Smads, Six,
and ERα), and in part through intrinsic DNA sequence-
specific binding properties via Forkhead binding sequences
[11–13]. DACH1 is expressed widely in normal adult tissues,
which functions as a tumor suppressor in a variety of malig-
nant tumors in previous studies. Wu K et al’s studies demon-
strated that DACH1 blocks mammary tumor growth through
downregulating Nanog and Sox2, and reduced DACH1 pro-
tein levels correlated significantly with poor prognosis of
breast cancer [14, 15]. Y. Yamada et al. revealed that lower
DACH1 level correlates with a poor prognosis of gastric can-
cer patients [16]. DACH1 level is also found decreased in
prostate cancer, and re-introduction of DACH1 inhibits pros-
tate cancer cell proliferation in vitro [13]. Recently, several
studies focused on the effects of DACH1 on the proliferation
and invasion of lung cancer cells. Ke Chen et al. identified
DACH1 as a novel p53 binding partner that participates in
p53-mediated induction of p21CIP1 and cell cycle arrest [12].
Na Han et al’s study revealed low expressions of DACH1
predicted unfavorable prognosis for survival, and CXCL5
was identified as a downstream target of DACH1-mediated
repression of cell invasion and tumorigenesis [17]. While in
this study, we identified that peroxiredoxin 3 (PRX3) is a key
target of DACH1.
PRX3 is a member of the peroxiredoxin family, which
contains a conserved N-terminal and participates in degrada-
tion of H2O2 [18]. PRX3 is specifically located in the mito-
chondria, which exhibits antioxidant properties, regulates cell
signaling and proliferation, protects protein structure, and
inhibits redox-dependent pathways of apoptosis activation,
acting as an important role in cell protection from oxidative
stress [19, 20]. In the past decades, more and more researches
demonstrated that PRX3 take parts in the development and
progression of malignant tumors. Jinxia Hu et al. revealed
that increased expression of PRX3 in cervical cancer is a
potential marker for cell proliferation [21]. Nonn et al. re-
ported that PRX3 played a protective role against drug-
induced oxidative stress and subsequent apoptosis of
thymoma cells [22]. Kalinina et al. revealed that an increase
in the expression of PRX3 was detected in cisplatin-resistant
cancer cells, including a cisplatin-resistant breast cancer cell
line (MCF-7), a cisplatin-resistant human erythroleukemia
cell line (K562), and a cisplatin-resistant human ovarian car-
cinoma cell line (SKOV-3), while this increased expression
protects cells from apoptosis and participates in the regula-
tion of cell proliferation [23].
In this study, we explored the aberrant status, cancer-related
functions, and potential tumor suppressing mechanisms of
DACH1 in lung adenocarcinoma tissues and cell lines. Our
results suggest that DACH1 acts as a tumor suppressor by
targeting PRX3 functional target genes in malignant lung
cells. More important, lower DACH1 expression significantly
correlated with tumor diameter and tumor invasion. All these
results demonstrated that DACH1 might be an efficient tumor
suppressor in lung adenocarcinoma tumor, which merits fur-
ther investigation in the clinic.
Materials and methods
Patients and specimens
Fresh-frozen human lung adenocarcinoma tissues (n=36) and
matched distant normal lung tissues were obtained from pa-
tients who underwent radical surgery between 7 April and 12
August, 2014, at Changhai Hospital affiliated to the Second
Military Medical University (Shanghai China) with informed
consent. The patients included 21 males and 15 females, with
an average age of 58 years. None of these patients received
radiotherapy or chemotherapy before surgical resection. All
36 cases were reviewed for histological subtype, differentia-
tion and tumor stage. The histological diagnosis and grade
were evaluated on hematoxylin and eosin-stained sections ac-
cording to the World Health Organization (WHO) guidelines
of classification. ACCP classification was used to classify
specimens as stages I (n=8), II (n=11), and IIIa (n=17) [24].
Cell culture
Two human lung adenocarcinoma cell lines (LTEP-α-2 and
A549) and a normal alveolar epithelium cell line (BEAS-2B)
were obtained from the American Type Culture Collection
(ATCC). Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Gibco, Carlsbad, USA) supplemented
with 10 % bovine calf serum (Gibco, Carlsbad, USA) and
maintained at 37 °C in an atmosphere of humidified air with
5 % CO2.
Immunohistochemistry
Immunohistochemical (IHC) analysis of human lung adeno-
carcinoma tissues and adjacent non-tumor tissues was con-
ducted using monoclonal DACH1 or PRX3 antibodies (Cell
Signaling Technology, USA, 1:1000 dilution) as in previous
descriptions [13]. Immunohistochemical staining scores were
evaluated as the percentage of positive cells and counted by
two independent persons not aware of the patient information.
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Western blotting
Whole cell/tissue lysates were harvested in ice-cold lysis buff-
er (10 mM Tris–HCl, 1 mM EDTA, 0.1 % Triton X-100 and
0.1 % SDS, pH=7.4) containing protease inhibitors (2 μg/mL
aprotinin, 10 μg/mL antipain, 2 μg/mL pepstatin, and 2 mM
benzamide). After the removal of cell debris by centrifugation
(12,000g×10 min), the protein concentration in the superna-
tants was measured using bicinchoninic acid protein assay
reagent (Pierce Chemical Co., Rockford, IL, USA) according
to the product information. Ten micrograms of total protein
were subjected to SDS-PAGE and immunoblotted with
DACH1/PRX3 antibodies (Cell Signaling Technology,
USA). GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) was used as a reference protein to analyze the DACH1
quantitatively [25].
Real-time PCR
Total RNAwas reverse transcribed into complementary DNA
(cDNA) by usingAMVReverse Transcriptase (Takara, Japan)
with oligo (dT) 18 or specific RT primer. Equal amounts of the
cDNA products were used as templates for subsequent PCR
amplification using the q-PCR thermal cycler (steponeplus,
ABI, USA). The oligonucleotide primer sequences used in
this research were illustrated in Supplementary Table 1.
Plasmid transfection
Cells were grown till 70–80 % confluence and respectively
transfected with vector (pcDNA), exogenously DACH1 ex-
pression plasmid (DACH1 pcDNA), and PRX3 expression
plasmid (PRX3 pcDNA) using Lipofectamine 2000
(Invitrogen Life Technologies, Carlsbad, CA, USA) according
to the manufacturer’s instructions, respectively. After 48 h,
cells were harvested, followed by limited dilution in a 96-
well plate for the generation of individual clones. Two weeks
later, cells were harvested for further experiments.
Dual-luciferase report assay
Dual-luciferase assay was performed as in previous de-
scription [26]. Briefly, the 3’UTR of the PRX3 gene
was cloned into the pGL3-basic vector to generate a
PRX3-pGL3 vector. Harvest cells were plated into a
24-well plate at approximately 80 % confluence, then
co-transfected with DACH1 and PRX3 expressed vec-
tors using lipofectamine 2000 transfection agents ac-
cording to the manufacturer’s protocol. Subsequent to
24 h of transfection, the cells were harvested, lysed,
and analyzed using the Dual-Luciferase Reporter Assay
System kit (Promega, USA). All the experiments were
performed in triplicate.
Cell cycle analysis
Harvested cells were re-suspended with 50 μg/ml propidium
iodide (PI, Sigma-Aldrich) for 30 min in the dark before anal-
ysis. The percentages of cells in different phases of cell cycle
were determined using a FACSCalibur Flow Cytometer with
Cell Quest 3.0 software (BD Biosciences). Experiments were
performed in triplicate.
Colony formation assay
Harvested cells were seeded into 6-cm cell culture dishes (500
per dish) and incubated at 37 °C for 2 weeks. Colonies were
visualized by 0.04% crystal violet staining, and colonies more
than 50 μm in diameter were counted using an Omnicon 3600
image analysis system.
Cell proliferation assays
Cell proliferation assays were performed according to previ-
ous descriptions [27]. Briefly, cells were seeded into 96-well
tissue culture plates at an initial density of 3000 cells/well in
100 μl of culture medium. After different time intervals, the
cell viability was determined with a Cell Counting Kit-8
(CCK-8, Dojindo Molecular Technologies, Oslo, Norway)
following the manufacturer’s protocol.
Statistical analysis
SPSS (version 16.0) for windows was used for all sta-
tistical analyses. The chi-squared test was used to ex-
amine possible correlations between DACH1 expression
and clinicopathologic factors. Pearson’s correlation coef-
ficient statistics method was used to examine the corre-
lations between levels of DACH1 expression and target
gene expression. P < 0.05 was considered statistically
significant.
Results
Reduced DACH1 expression in both lung
adenocarcinoma tissues and cells
In order to determine the alteration of DACH1 expression in
lung cancer, we performed Western blotting (WB) and IHC
analysis of DACH1 levels between the 36 pairs of lung ade-
nocarcinoma tissues and adjacent non-tumor tissues.
Figure 1a, b respectively demonstrates the representative
IHC and WB photos, from which we can see that DACH1,
which confined to the nuclear of normal and malignant pul-
monary epithelial cells, is obviously downregulated in lung
adenocarcinoma tissues. Consistent results were obtained in
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cultured cell lines by WB with the results shown in the
right panel of Fig. 1b, which reveals that comparing
with BEAS-2B cells (a normal alveolar epithelium cell
line), DACH1 expression was significantly decreased in
both two lung adenocarcinoma cell lines, LTEP-α-2 and
A549. The relatively low expression of DACH1 in lung
adenocarcinoma tissues and cells was validated by real-
time PCR (RT-PCR) analysis, with results showing in
Fig. 1c, d (*p< 0.05, **p< 0.01).
PRX3 was significantly upregulated in both lung
adenocarcinoma tissues and cells
Similar experiments were also employed to compare the
expression of PRX3 in normal and malignant lung tissues
and cells. Figure 2a, b respectively demonstrates the rep-
resentative IHC and WB photos, from which we can see
that the expression of PRX3, which confined to the cyto-
plasm of normal and malignant pulmonary epithelial cells,
Fig. 1 Decreased DACH1
expression in lung cancer tissues
and cells. a Representative photos
of immunohistochemistry for
DACH1 in pairs of lung cancer
tissues and adjacent non-tumor
tissues (scale bar 50 μm). b Left
panel: representative photos of
Western blotting for DACH1 in
pairs of lung cancer tissues and
adjacent non-tumor tissues. Right
panel: Western blotting analysis
for DACH1 expression in LTEP-
α-2, A549, and BEAS-2B cells.
c–d Relative levels of DACH1 in
normal and malignant tissues (c)
and cells (d) by real-time PCR
analysis. Data are shown as mean
± SEM, *p< 0.05, **p < 0.01
Fig. 2 Increased PRX3
expression in lung cancer tissues
and cells. a Representative photos
of immunohistochemistry for
PRX3 in pairs of lung cancer
tissues and adjacent non-tumor
tissues (scale bar 50 μm). b Left
panel: representative photos of
Western blotting for PRX3 in
pairs of lung cancer tissues and
adjacent non-tumor tissues. Right
panel: Western blotting analysis
for PRX3 expression in LTEP-α-
2, A549, and BEAS-2B cells. c–d
Relative levels of PRX3 in
normal and malignant tissues (c)
and cells (d) by real-time PCR
analysis. Data are shown as mean
± SEM, *p< 0.05, **p < 0.01
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is significantly increased in lung adenocarcinoma tissues
and cells. Also, RT-PCR was used to compare the mes-
senger RNA (mRNA) levels of PRX3 in normal and ma-
lignant lung epithelial tissues and cells. Figure 2c demon-
strates that the average level of PRX3 mRNA was
significantly decreased in all the 36 collected lung adeno-
carcinoma tissues (*p< 0.05) in comparison with normal
tissues. In accordance, the levels of PRX3 in both
LTEP-α-2 and A549 cells were remarkably higher than
that in BEAS-2B cells (**P< 0.01, Fig. 2d).
Fig. 3 PRX3 may be a direct target of DACH1 in vitro. a The luciferase
activity was significantly lower when transfected with DACH1 but not
empty vectors in both LTEP-α-2 and A549 cells. b Transfection with
DACH1 can remarkably downregulate cellular PRX3 expression in
both LTEP-α-2 and A549 cells by real-time PCR analysis. c Western
blotting analysis for DACH1 and PRX3 expression in wild-type and
DACH1 transfected lung cancer cells (LTEP-α-2 and A549). Data are
shown as mean± SEM (n = 3), **p< 0.01
Fig. 4 The influence of PRX3
and DACH1 on migration ability
and cell cycle arrest of lung
cancer cells. a Colony-forming
assays comparing wild-type lung
cancer cells and cells transfected
with DACH1 and PRX3. b Cell
cycle distribution analysis of both
LTEP-α-2 and A549 cells
transfected with DACH1 and
PRX3 in comparison with wild-
type cells by flow cytometry
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Overexpression of DACH1 downregulates PRX3 levels
in lung cancer cells
Considering the downregulation of DACH1 (Fig. 1) and up-
regulation of PRX3 (Fig. 2) expression in human lung adeno-
carcinoma cells and tissues, we hypothesized that there may
be a negative correlation between their intracellular levels. In
order to verify this hypothesis, the luciferase reporter system
was employed to investigate the regulatory role of DACH1 in
the expression of PRX3. Figure 3a revealed that transfection
of DACH1 but not empty vectors significantly decreased the
luciferase levels expressed in both lung cancer cells
(**P<0.01). The results were confirmed by direct detection
of PRX3 levels by RT-PCR and WB analysis. As we can see
from Fig. 3b–c, the intracellular levels of PRX3 in both
mRNA and protein levels experienced a significant decrease
in DACH1-transfected cancer cells (**P<0.01).
Overexpression of DACH1 inhibits cell proliferation
and migration of lung adenocarcinoma cells
In order to investigate the influence of DACH1 on cell prolif-
eration and invasion, wild-type lung cancer cells and cells in-
fected with DACH1 or empty vectors (NC) were employed in
the subsequent studies. The colony formation assay revealed
that the counts of colonies formed by DACH1-transfected lung
adenocarcinoma cells were much less than those of WT cells
(Fig. 4a). Figure 4b demonstrates that both lung adenocarcino-
ma cells were enriched at S and G2/M phases when DACH1
was overexpressed (**P<0.01). Similar results were obtained
in cell proliferation assays, the results of which (Fig. 5a) reveals
that subsequent to a 5-day-period, cell proliferation ability was
lower in DACH1 transfection groups than in the non-
transfection (WT) and mock-vehicle groups (NC). The remark-
able decrease was firstly observed on day 2. It should be noted
here that the negative regulating roles of DACH1 on cell pro-
liferation and invasion can be significantly prevented by co-
transfection of PRX3 (Figs. 4 and 5). All these results clearly
indicate that the overexpression of DACH1 can successfully
inhibit cellular proliferation and migration of lung cancer cells
through the downregulation of PRX 3.
Clinical significance of DACH1 protein expression in lung
adenocarcinoma
In order to study the clinical relevance of DACH1 expression
and lung cancer development, this study enrolled 36 patients
diagnosed with lung adenocarcinoma ranged from 45 to
74 years, and the mean age at the time of surgery was
58.0 years. Of these patients, 21 were men (77%) and 15 were
women (23 %). Based on the ACCP classification [24], 8
patients were at stage I, 11 were at stage II, and 17 were at
stage IIIa. The relative expression of DACH1 in resected lung
samples were determined by WB, IHC, and RT-PCR assays
(Fig. 1). We next analyzed the correlation between the levels
of cellular DACH1 protein and the clinic-pathological param-
eters of the patients. As shown in Table 1, lower DACH1
expression significantly correlated with tumor diameter
(*P=0.043) and tumor invasion (*P=0.045). By contrast,
no significant association was found between DACH1 down-
regulation and age, gender, nodal status, or degree of differ-
entiation. These results suggest that DACH1 have physiolog-
ical function in lung adenocarcinoma proliferation and
progression.
Fig. 5 The influence of PRX3 and DACH1 on proliferation of lung
cancer cells. a Viability of wild-type LTEP-α-2 cells and cells infected
with DACH1 with or without PRX3 by CCK-8 assays. b Viability of
wild-type A549 cells and cells infected with DACH1 with or without
PRX3 by CCK-8 assays. Data are shown as mean ± SD, *p < 0.05,
**p< 0.01
Table 1 Relationship between DACH1 expression and clinical
pathologic parameters
Variables N= 36 DACH1 expression p value
high (n= 19) low (n = 17)
Age (years) 0.676
≤50 14 8 6
>50 22 11 11
Gender 0.535
Male 21 12 9
Female 15 7 8
Tumor diameter (cm) 0.043 *
≤2 19 7 12
>2 17 12 5
Degree of differentiation 0.194
Poor 15 6 9
Well to moderate 21 13 8
Tumor invasion (T) 0.045*
T1/T2 32 15 17
T3 4 4 0
Nodal status (N) 0.923
N0 13 7 6
N+ 23 12 11
*Statistically significant (p< 0.05)
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Discussion
In the past 100 years, lung cancer has been transformed from a
rare disease into a serious global problem [1, 4]. Although
significant advances have been made with conventional ther-
apies, lung cancer still remains the leading cause of cancer-
related mortality among both men and women [1, 4, 5], the
fact of which calls for improvements in the diagnosis and
treatment of the disease. Although the EGFR tyrosine kinase
inhibitors gefitinib and erlotinib have revolutionized the treat-
ment of lung cancers, only patients with activating mutations
of the EGFR gene respond to the therapy [9]. Also, patients
rapidly develop drug resistance during the course of therapy
[10], the fact of which highlights the importance of finding out
novel therapeutic targets in treating lung cancer.
The DACH1 gene is a member of the RDGN that regulates
retinal cell fate determination [11]. Recently, DACH1 was
shown to suppress the growth and invasion of tumor cells in
a variety of researches [12–15, 28]. However, the biological
function of DACH1 in lung cancer is still not well understood.
In this study, we have identified reduced DACH1 expression
in lung adenocarcinoma tissues and cells compared to normal
tissues and cells, respectively. As a transcription factor,
DACH1 likely inhibits tumor growth and progression via tran-
scriptional regulation of target gene expression. Indeed, our
in vitro experiment confirmed the growth inhibitory function
of DACH1 when overexpressed in lung cancer cells. Further-
more, DACH1 overexpression disrupted cell cycle progres-
sion. Consistently, several recent studies reported tumor sup-
pressor function in breast cancer and prostate cancer, and ex-
hibited cell cycle regulatory function [13, 15].
Our study also determined that DACH1 significantly
downregulates PRX3 gene expression, which is overexpressed
in both of the two lung cancer cells employed in this study.
Moreover, we observed a negative correlation betweenDACH1
and PRX3 expression in clinical lung adenocarcinoma samples
and cultured cancer cells. When compared to wild-type lung
cancer cells, DACH1 overexpression in LTEP-α-2 and A549
cells blocks cell cycle progression and thus negatively influence
tumor cell growth and invasion, while this alteration can be
significantly prevented by the co-infection of PRX3. Recently,
Zhou et al. demonstrated that DACH1 may inhibit cell cycle
progression by competing with FOXM1 for promoter occupa-
tion and transcriptional regulation of several cell cycle-related
genes [11]. It has been reported that FOXM1 can bind to the
PRX3 promoter region containing a FOXM1-binding site [29,
30]. Sung Song et al’s study demonstrated that FOXM1 can
transcriptionally activate PRX3 and the stem cell marker
CD133, maintaining the stemness in colon cancer stem cells
(CSCs) by promoting mitochondrial function [31]. Considering
our experimental results and previous publications, it can be
concluded that the inhibitory role of DACH1 in the proliferation
and invasion of lung adenocarcinoma should be ascribed to the
downregulation of its transcriptional target, Prx3, by competing
with FOXM1 for promoter binding.
However, Jae-Woong Lee et al’s study demonstrated oppo-
site roles of DACH1 associated with the regulation of the cell
cycle machinery and expression of reprogramming factors in
myeloid cells [28]. Therefore, it seems that the effect of
DACH1 associated with cell fate determination and tumori-
genesis has to be differentially considered in different types of
tumors. Moreover, this discrepancy suggests the complexity
of gene regulation in cancer tissues. We speculate that such
gene regulation maybe context dependent, and DACH1 may
positively or negatively regulate gene expression through
binding to different co-factors [11].
Besides, our study is the first study to statistically reveal that
low expression of DACH1 significantly correlated with tumor
diameter and invasion in 36 patients diagnosed with lung ade-
nocarcinoma tumor. Thus, downregulation of DACH1 in lung
cancer tissues might be an adverse prognostic factor, which
should be extensively evaluated in further studies. We will fur-
ther validate our findings in a larger population in future studies.
In conclusion, the present study demonstrates that DACH1
acts as a potential tumor suppressor in lung cancer tissues and
cells through the downregulation of PRX3 expression. Down-
regulation of DACH1 suggests unfavorable prognosis of lung
cancers. All these results indicate that PRX3 might be a novel
and ideal target for targeting therapy, which merits further
evaluation in the clinic.
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